Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024.
Bloomberg | Bloomberg | Getty Photos
LONDON — Shares of Denmark’s Zealand Pharma popped approximately 23% in Friday early morning deals, notching a record higher soon after an early-phase analyze of its fat decline drug challenger made favourable success.
The business explained Thursday that a class of 16 weekly large doses of very long-acting amylin analog petrelintide diminished human body pounds by up to 8.6% on normal in the review. A placebo drug led to a overall body excess weight reduce of 1.7%.
A single out of 48 review participants withdrew thanks to damaging results.
Petrelintide was “judged to be harmless and properly tolerated at all dose amounts,” and the final results furnished “sturdy aid” for its opportunity as an choice to GLP-1 receptor agonist-based mostly therapies for fat administration, Zealand Pharma claimed in a launch.
GLP-1RA-primarily based treatment options involve Ozempic, the diabetes drug developed by fellow Danish pharmaceutical agency Novo Nordisk, which has exploded in level of popularity globally for its fat-reduction results. Soaring need for Ozempic and being overweight drug Wegovy have propelled Novo Nordisk to turn into Europe’s most valuable business.
The final few decades have found an ever-intensifying race to deliver rival treatments, drawing in dozens of challengers to current market leaders Novo Nordisk and Eli Lilly in the United States.
David Kendall, main health-related officer of Zealand Pharma, explained that the petrelintide analyze supports the company’s conviction that the drug “is extremely properly tolerated and can perhaps enjoy an vital position as an option to incretin-based mostly therapies for the management of overweight and being overweight.”
It could “supply body weight loss equivalent to GLP-1 receptor agonists with a greater patient expertise,” Kendall additional.
The corporation now plans to check petrelintide in a period 2 mid-phase clinical demo.
Analysts at Jefferies stated in a Thursday be aware that the preliminary benefits show that the drug “ticks all the bins.” They guidance a “possible job for amylin as a far more tolerable substitute to GLP-1s,” with the potential for bodyweight reduction “at minimum on a par.”
Zealand Pharma is individually tests the opportunity body weight decline drug survodutide in a partnership with Germany’s Boehringer Ingelheim. Favourable stage 2 demo outcomes for that drug in February boosted Zealand’s share rate at the time.
Zealand Pharma share price.
